Kit receptor tyrosine kinase dysregulations in feline splenic mast cell tumours. (9th June 2016)

• Record Type: Journal Article
• Authors: Sabattini, S.; Barzon, G.; Giantin, M.; Lopparelli, R. M.; Dacasto, M.; Prata, D.; Bettini, G.
• Is Part Of: Veterinary and comparative oncology. Volume 15:Number 3(2017:Sep.)
• Page Start: 1051
• Page End: 1061
• Publication Date: 2016-06-09
• Subjects: CD117 -- feline -- Kit -- mast cell tumour -- spleen -- tyrosine kinase; Veterinary oncology -- Periodicals; Neoplasms -- veterinary -- Periodicals; 636.0896994005
• DOI: 10.1111/vco.12246
• Languages: English
• ISSNs: 1476-5810

Abstract

Abstract: This study investigated Kit receptor dysregulations (cytoplasmic immunohistochemical expression and/or c‐KIT mutations) in cats affected with splenic mast cell tumours. Twenty‐two cats were included. Median survival time was 780 days (range: 1–1219). An exclusive splenic involvement was significantly ( P = 0.042) associated with longer survival (807 versus 120 days). Eighteen tumours (85.7%) showed Kit cytoplasmic expression (Kit pattern 2, 3). Mutation analysis was successful in 20 cases. Fourteen missense mutations were detected in 13 out of 20 tumours (65%). Eleven (78.6%) were located in exon 8, and three (21.6%) in exon 9. No mutations were detected in exons 11 and 17. Seven mutations corresponded to the same internal tandem duplication in exon 8 (c.1245_1256dup). Although the association between Kit cytoplasmic expression and mutations was significant, immunohistochemistry cannot be considered a surrogate marker for mutation analysis. No correlation was observed between c‐Kit mutations and tumour differentiation, mitotic activity or survival.